[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Yoshii T, Horiguchi A, Shirotake S, Tobe M, Hayakawa M, Sumitomo M, Asano T: [Spontaneous rupture of the ureter as the primary symptom of malignant lymphoma]. Hinyokika Kiyo; 2010 Nov;56(11):639-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spontaneous rupture of the ureter as the primary symptom of malignant lymphoma].
  • We report a rare case in which upper ureteral rupture was the primary symptom of malignant lymphoma.
  • Computed tomography showed urinoma around the left kidney and retrograde pyelography showed a diffuse filling defect in the left ureter and a rupture of the upper portion of that ureter.
  • A urine cytology specimen from the left ureter was class V, suggesting undifferentiated carcinoma or malignant lymphoma.
  • An open laparotomy revealed a nodule on the omentum and diffuse fibrosis around both ureters, and the histopathological diagnosis was diffuse large B-cell lymphoma.
  • The patient' s ureteral stenosis disappeared after she received six cycles of R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone and rituximab) chemotherapy.
  • We should be aware that malignant lymphoma can be the cause of a spontaneous ureteral rupture.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / complications. Ureteral Diseases / etiology

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Ureteral Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187710.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Nishizawa K, Nakamura E, Kobori G, Kobayashi T, Yamamoto S, Kamoto T, Okuno H, Terai A, Kakehi Y, Ogawa O, Ueda H, Yamaoka T, Kadowaki N: [A case of giant perirenal malignant lymphoma: a case report]. Hinyokika Kiyo; 2002 Mar;48(3):175-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of giant perirenal malignant lymphoma: a case report].
  • We report a case of malignant lymphoma arising as a giant perirenal mass in a 62-year-old woman who presented with an enlarging abdominal mass.
  • Computed tomography (CT) revealed a large homogeneous mass with a diameter of 20 cm arising in the retroperitoneum.
  • It surrounded the left kidney without renal infiltration and accompanied with para-aortic lymph node enlargement.
  • On the basis of these imaging studies, the tumor was diagnosed as lymphoma.
  • Then, a US guided percutaneous biopsy was performed and the tumor was diagnosed as malignant B-cell lymphoma by the histopathological analysis.
  • This patient was treated by systemic chemotherapy since tumor cells were also disseminated in the bone marrow.
  • The tumor responded well to the chemotherapy and about 70% of regression was achieved after six courses of chemotherapy.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Retroperitoneal Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Kidney / pathology. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11993214.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. García-Suárez J, de Miguel D, Krsnik I, Barr-Alí M, Hernanz N, Burgaleta C: Spontaneous gas gangrene in malignant lymphoma: an underreported complication? Am J Hematol; 2002 Jun;70(2):145-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous gas gangrene in malignant lymphoma: an underreported complication?
  • We report a case of spontaneous gas gangrene (SGG), the most rapidly progressive form of clostridial infection, in a patient with non-Hodgkin's lymphoma (NHL).
  • A 43-year-old man with NHL developed fatal C. perfringens-associated SGG and massive hemolysis during induction chemotherapy.
  • Common features of all reports are a delayed diagnosis and a fatal outcome.
  • Awareness of this condition should result in prompt antibiotic therapy at the onset of typical presenting symptoms in any lymphoma patient, especially if risk factors are present.
  • [MeSH-major] Gas Gangrene / complications. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Acute Kidney Injury / etiology. Adult. Clostridium perfringens. Disseminated Intravascular Coagulation / etiology. Fatal Outcome. Hemolysis. Humans. Male. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12111788.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


Advertisement
4. Shiga Y, Suzuki K, Tsutsumi M, Ishikawa S: Transitional cell carcinoma of the renal pelvis in a patient with cyclophosphamide therapy for malignant lymphoma: a case report and literature review. Hinyokika Kiyo; 2002 May;48(5):301-5
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the renal pelvis in a patient with cyclophosphamide therapy for malignant lymphoma: a case report and literature review.
  • A 59-year-old man, who had received cyclophosphamide therapy for malignant lymphoma, was suffering from gross hematuria and consulted our institute.
  • Computerized tomography (CT), intravenous pyelography (IVP) and retrograde pyelography (RP) revealed a left renal pelvic tumor.
  • Histopathological diagnosis of the left renal pelvic tumor was transitional cell carcinoma, invading the renal parenchyma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Carcinoma, Transitional Cell / chemically induced. Cyclophosphamide / adverse effects. Kidney Neoplasms / chemically induced. Lymphoma / drug therapy. Neoplasms, Second Primary / chemically induced
  • [MeSH-minor] Humans. Kidney Pelvis. Male. Middle Aged


5. Weng SC, Shu KH, Wen MC, Cheng CH, Wu MJ, Yu TM, Chuang YW, Chen CH: Malignant lymphoma of the kidney mimicking rapid progressive glomerulonephritis. Clin Nephrol; 2010 Dec;74(6):480-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma of the kidney mimicking rapid progressive glomerulonephritis.
  • Primary renal lymphoma (PRL) is rare and often presents as rapidly progressive renal failure.
  • Herein, we report a 75-year-old female patient with infiltrative CD20 (+) B-cell lymphoma who underwent 4 consecutive courses of chemotherapy with R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone) and after 12 sessions became free from hemodialysis in good general condition.
  • Unfortunately, a relapse of CD20 (-) lymphoma developed rapidly involving other organs.
  • She died with severe hospital-acquired pneumonia and febrile neutropenia after the last chemotherapy with R-MINE almost 1 year after onset of symptoms.
  • We conclude that renal biopsy enables prompt diagnosis in rapidly progressive renal failure and immunophenotyping and also staging workup of the lymphoma in case of positive biopsy.
  • This may relate to frequent relapse/resistance after rituximab therapy and poor long-term patient survival.
  • [MeSH-major] Glomerulonephritis / diagnosis. Kidney Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Aged. Antigens, CD20 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Predictive Value of Tests. Renal Dialysis. Renal Insufficiency / etiology. Renal Insufficiency / therapy. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Glomerulonephritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084053.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD20
  •  go-up   go-down


6. Végso G: [Post-transplantation malignant tumors and the challenges of immunosuppressive therapy in transplanted patients developing lymphoma. Mycophenolic acid as a possibility]. Magy Onkol; 2009 Jun;53(2):149-56
Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Post-transplantation malignant tumors and the challenges of immunosuppressive therapy in transplanted patients developing lymphoma. Mycophenolic acid as a possibility].
  • The increasing frequency of malignant tumors developing during chronic immunosuppression is an important determinant of the long-term survival of organ transplanted patients.
  • The incidence and frequency of tumors occurring in kidney transplant recipients differ from those of the Hungarian population.
  • The increased tumor risk resulting from chronic renal failure, increasing age of prospective kidney recipients and, in addition, the increasing frequency of tumors diagnosed in the early post-transplantation period emphasize the importance of regular oncological screening of patients on the waiting list.
  • Early diagnosis and treatment of tumors and precancerous conditions are equally important in transplanted patients as well, and the tumor risk could be decreased by applying low dose immunosuppression and the preferential usage of immunosuppressive drugs with an oncologically favorable effect.
  • The prognosis of post-transplantation tumors is poor, as they respond poorly to therapy.
  • Different immunosuppressive regimens represent varying degrees of risk in lymphoma development.
  • The composition of immunosuppression is a major factor in treatment; an oncologically ideal compound would prevent organ rejection and, at the same time, would not counteract oncological therapy.
  • The favorable properties of mycophenolic acid suggest that it can provide the necessary immunoprotection for the transplanted organ and, given its anti-lymphoma effects, it may also prove useful in the therapy of lymphoma patients.
  • It may also be helpful in the treatment of "traditional" lymphomas of the non-transplanted population, where the major cause of therapeutical failure is the development of apoptosis resistance.
  • Mycophenolic acid, combined with other chemotherapeutical drugs, may enhance apoptosis in lymphoma cells.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Immunosuppressive Agents / adverse effects. Lymphoma / drug therapy. Lymphoma / immunology. Mycophenolic Acid / therapeutic use. Organ Transplantation / adverse effects
  • [MeSH-minor] Adult. Aged. Animals. Female. Humans. Hungary / epidemiology. Kidney Transplantation / adverse effects. Male. Middle Aged. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581181.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunosuppressive Agents; HU9DX48N0T / Mycophenolic Acid
  •  go-up   go-down


7. Cohen LJ, Rennke HG, Laubach JP, Humphreys BD: The spectrum of kidney involvement in lymphoma: a case report and review of the literature. Am J Kidney Dis; 2010 Dec;56(6):1191-6
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The spectrum of kidney involvement in lymphoma: a case report and review of the literature.
  • Kidney involvement is an under-recognized complication of both Hodgkin and non-Hodgkin lymphoma.
  • The diversity of lymphoma-related renal manifestations makes diagnosis difficult.
  • Although abrupt worsening of kidney function may be the first sign of malignant disease, renal effects can be subtle or even silent.
  • We discuss a case of non-Hodgkin lymphoma and associated kidney failure from several distinct malignancy-related mechanisms and review the spectrum of lymphoma-related kidney involvement.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Am Soc Nephrol. 2002 May;13(5):1238-47 [11961011.001]
  • [Cites] Blood. 2010 May 6;115(18):3756-62 [20200355.001]
  • [Cites] Am J Kidney Dis. 2003 Nov;42(5):960-71 [14582040.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):1041-4 [15297973.001]
  • [Cites] Lancet. 1974 Sep 7;2(7880):556-60 [4140273.001]
  • [Cites] Kidney Int. 1977 May;11(5):297-303 [197291.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):874-5 [4016678.001]
  • [Cites] Am J Med. 1986 Jan;80(1):63-70 [3510541.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):748-53 [3524795.001]
  • [Cites] Kidney Int. 1986 Oct;30(4):465-73 [3537450.001]
  • [Cites] Postgrad Med J. 1986 Dec;62(734):1141-5 [3309913.001]
  • [Cites] Kidney Int. 1991 Sep;40(3):453-60 [1787645.001]
  • [Cites] Am J Kidney Dis. 1992 Mar;19(3):201-13 [1553965.001]
  • [Cites] Am J Kidney Dis. 1992 Jul;20(1):84-9 [1621685.001]
  • [Cites] Kidney Int. 1992 Jul;42(1):127-35 [1635342.001]
  • [Cites] Nephrol Dial Transplant. 1996 May;11(5):837-42 [8671905.001]
  • [Cites] J Am Soc Nephrol. 1997 Aug;8(8):1348-54 [9259365.001]
  • [Cites] Kidney Int. 1999 Jul;56(1):355-77 [10411717.001]
  • [Cites] Am J Med. 1962 Feb;32:184-207 [14492019.001]
  • [Cites] Kidney Int. 2006 Jun;69(12):2251-60 [16672913.001]
  • [Cites] Kidney Int. 2006 Oct;70(8):1510-7 [16941021.001]
  • [Cites] Clin Exp Nephrol. 2006 Dec;10(4):284-9 [17186334.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Nov;1(6):1331-41 [17699366.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Nov;1(6):1342-50 [17699367.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Nov;1(6):1351-6 [17699368.001]
  • [Cites] Am J Kidney Dis. 2007 Sep;50(3):396-403 [17720518.001]
  • [Cites] J Nephrol. 2007 Sep-Oct;20(5):626-8 [17918150.001]
  • [Cites] Hematol Oncol. 2009 Mar;27(1):31-9 [18924115.001]
  • [Cites] Pediatr Nephrol. 2009 Sep;24(9):1691-8 [19495805.001]
  • [Cites] J Am Soc Nephrol. 2002 May;13(5):1390-7 [11961029.001]
  • (PMID = 20843590.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK073628; United States / NIDDK NIH HHS / DK / DK084316; United States / NIDDK NIH HHS / DK / R03 DK084316-01; United States / NIDDK NIH HHS / DK / K08 DK073628-05; United States / NIDDK NIH HHS / DK / DK073628; United States / NIDDK NIH HHS / DK / T32 DK007527; United States / NIDDK NIH HHS / DK / R03 DK084316; United States / NIDDK NIH HHS / DK / K08 DK073628-04
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 4F4X42SYQ6 / Rituximab; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone
  • [Other-IDs] NLM/ NIHMS332584; NLM/ PMC3222147
  •  go-up   go-down


8. Takagi Y, Senda M, Tanaka J: [Renal cell carcinoma in a patient with malignant lymphoma: a case report]. Hinyokika Kiyo; 2000 Aug;46(8):545-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal cell carcinoma in a patient with malignant lymphoma: a case report].
  • A 65-year-old woman was admitted for the treatment of malignant lymphoma.
  • Computed tomography revealed a right renal tumor.
  • After 3 cycles of CHOP (cyclophosphamide, adriamycin, vincristine, prednisone) chemotherapy, we performed right radical nephrectomy.
  • The histopathological diagnosis was renal cell carcinoma.
  • After nephrectomy she was treated with 3 cycles of CHOP chemotherapy and radiation therapy.
  • She received no adjuvant therapy for renal cell carcinoma and had no recurrence after 8 months from the nephrectomy.
  • [MeSH-major] Carcinoma, Renal Cell / therapy. Kidney Neoplasms / therapy. Lymphoma, B-Cell / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Nephrectomy. Prednisone / administration & dosage. Radiotherapy, Adjuvant. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11019373.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


9. Batchelor DJ, Bright SR, Ibarrola P, Tzannes S, Blackwood L: Long-term survival after combination chemotherapy for bilateral renal malignant lymphoma in a dog. N Z Vet J; 2006 Jun;54(3):147-50
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after combination chemotherapy for bilateral renal malignant lymphoma in a dog.
  • CLINICAL FINDINGS AND DIAGNOSIS: Radiography and ultrasonography revealed bilateral renomegaly, and cytology of fine needle aspirates from the kidneys was diagnostic of malignant lymphoma.
  • The dog was treated with a modified high-dose cyclophosphamide-, vincristine-, and prednisolone-based chemotherapy protocol, achieved remission, and returned to normal quality of life.
  • Survival time was 346 days from the time of diagnosis.
  • CLINICAL RELEVANCE: Malignant lymphoma in the kidneys of dogs has been considered to carry a uniformly poor prognosis.
  • Long-term remission after medical treatment has not previously been reported.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dog Diseases / drug therapy. Kidney Neoplasms / drug therapy. Lymphoma / drug therapy
  • [MeSH-minor] Animals. Dogs. Male. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16751846.001).
  • [ISSN] 0048-0169
  • [Journal-full-title] New Zealand veterinary journal
  • [ISO-abbreviation] N Z Vet J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  •  go-up   go-down


10. Taylor AL, Bowles KM, Callaghan CJ, Wimperis JZ, Grant JW, Marcus RE, Bradley JA: Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. Transplantation; 2006 Aug 15;82(3):375-81
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation.
  • BACKGROUND: Recommended first-line treatment for posttransplant lymphoproliferative disorder (PTLD) is reduction in immunosuppressive therapy, irrespective of histopathological type.
  • Second-line treatment with chemotherapy is generally reserved for tumors that fail to respond to reduced immunosuppression.
  • In view of the similarities between monomorphic PTLD and non-Hodgkin's lymphoma in the general population, our policy is to treat monomorphic PTLD with anthracycline-based chemotherapy as first-line treatment.
  • METHODS: A retrospective single-center analysis of 18 adults who developed PTLD following liver or kidney transplantation was undertaken, with particular emphasis on tumor histology, treatment received, and clinical outcome.
  • RESULTS: Of the 18 patients with PTLD, 13 had high-grade malignant lymphoma on diagnostic biopsy and received anthracycline-based chemotherapy and reduction in immunosuppression as first-line therapy.
  • Nine (69%) of the 13 patients achieved complete remission and eight (62%) remained in complete remission five years after diagnosis.
  • There was no graft loss from rejection or drug toxicity.
  • Four (22%) patients had polymorphic PTLD on diagnostic biopsy (of which two were re-classified as monomorphic) and one had a low-grade malignant lymphoma.
  • All five patients were treated by reduction in immunosuppression without chemotherapy and were in complete remission at a median of two years after diagnosis.
  • Overall, complete remission was seen in 14 out of 18 patients (78%) at one year following diagnosis.
  • CONCLUSION: The use of anthracycline-based chemotherapy and reduction of immunosuppression as first-line treatment in adults with monomorphic PTLD is well tolerated and achieves sustained complete remission in around 70% of patients with a low risk of graft loss.
  • [MeSH-major] Anthracyclines / therapeutic use. Kidney Transplantation. Lymphoma / drug therapy. Lymphoma / pathology. Lymphoproliferative Disorders / drug therapy. Lymphoproliferative Disorders / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16906036.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines
  •  go-up   go-down


11. Kubota Y, Kawai A, Tsuchiya T, Kozima K, Yokoi S, Deguchi T: Bilateral primary malignant lymphoma of the ureter. Int J Clin Oncol; 2007 Dec;12(6):482-4
Genetic Alliance. consumer health - Primary malignant lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral primary malignant lymphoma of the ureter.
  • The patient's right kidney was nonfunctional; therefore, right nephroureterectomy was performed for the purpose of pathologic diagnosis.
  • Histopathologic examination revealed follicular lymphoma with diffuse change in the ureter.
  • With chemotherapy for malignant lymphoma, the stenosis of the left ureter was alleviated, and left renal function was preserved.
  • Primary malignant lymphoma of the ureter is extremely rare.
  • In cases of ureteral stenosis with ureteral wall thickening for which the cause is uncertain, the possibility of malignant lymphoma of the ureter should be considered.
  • [MeSH-major] Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / surgery. Urethral Neoplasms / diagnosis. Urethral Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 1999 Jan;83(1):148-9 [10233472.001]
  • [Cites] Radiat Med. 2002 Jan-Feb;20(1):41-4 [12002603.001]
  • [Cites] Eur Radiol. 1999;9(2):344-6 [10101660.001]
  • [Cites] Hinyokika Kiyo. 2005 Apr;51(4):269-72 [15912788.001]
  • [Cites] Hinyokika Kiyo. 2004 Oct;50(10):721-4 [15575226.001]
  • [Cites] Urology. 1993 May;41(5):494-8 [8488622.001]
  • [Cites] Abdom Imaging. 1995 Mar-Apr;20(2):173-5 [7787726.001]
  • [Cites] J Comput Assist Tomogr. 1988 Jan-Feb;12 (1):157-8 [3335659.001]
  • [Cites] Urol Radiol. 1992;14 (3):183-7 [1290208.001]
  • (PMID = 18071870.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Zbiti N, Alhamany Z, Houssaini TS, Rhou H, Benamar L, Ezaitouni F, Bayahia R, Ouzeddoun N: [Acute renal failure due to malignant lymphoma infiltration]. Nephrol Ther; 2010 Dec;6(7):602-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute renal failure due to malignant lymphoma infiltration].
  • [Transliterated title] Lymphome rénal révélé par une insuffisance rénale aiguë.
  • We present two cases of renal lymphoma revealed by acute renal failure (ARF), which remains a rare clinical entity.
  • The diagnosis was a primitive kidney immunophenotype B lymphoma.
  • The patient died after three courses of chemotherapy due to rapid spread lymphoma.
  • The second case was a high-grade renal lymphomatous infiltration, with an unusual computer tomography image of two large kidneys compressing the stomach.
  • Death happened early before initiating therapy.
  • In both cases the diagnosis has been established by renal pathology.
  • Early diagnosis is a key component of therapeutic success, however, the rapid spread of lymphoma worsened renal and vital prognosis.
  • [MeSH-major] Acute Kidney Injury / etiology. Kidney Neoplasms / complications. Lymphoma, B-Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.
  • (PMID = 20920898.001).
  • [ISSN] 1872-9177
  • [Journal-full-title] Néphrologie & thérapeutique
  • [ISO-abbreviation] Nephrol. Ther.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


13. Bolanowski M, Kuliszkiewicz-Janus M, Sokolska V: Diffuse malignant lymphoma type B with optic chiasm infiltration, visual disturbances, hypopituitarism, hyperprolactinaemia and diabetes insipidus. Case report and literature review. Endokrynol Pol; 2006 Nov-Dec;57(6):642-7
Genetic Alliance. consumer health - Hypopituitarism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse malignant lymphoma type B with optic chiasm infiltration, visual disturbances, hypopituitarism, hyperprolactinaemia and diabetes insipidus. Case report and literature review.
  • The case is reported of a 55-year-old man with diffuse malignant lymphoma type B associated with transient optic chiasm infiltration and visual disturbances but with persistent hypopituitarism, hyperprolactinaemia and diabetes insipidus.
  • The patient was administered chemotherapy and radiotherapy.
  • Repeated MR and CT scans showed optic chiasm infiltration, which disappeared in the course of the chemotherapy but then recurred, changed its appearance and finally disappeared again.
  • In the meantime visual disturbances occurred and disappeared during the therapy.
  • Hypopituitarism, diabetes insipidus and hyperprolactinaemia were diagnosed and replacement therapy was administered.
  • Later on abdominal pain occurred, and a CT scan revealed bilateral kidney masses and enlarged retroperitoneal lymph nodes.
  • These were diffuse malignant lymphoma with regional lymphonodulitis in histology.
  • The length of survival time documented following the hypothalamochiasmatic infiltration and diagnosis of lymphoma makes the case an unusual one for patients with CNS lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / complications

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes Insipidus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17253438.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


14. Katsura Y, Suzukawa K, Kojima H, Yoshida C, Shimizu S, Mukai H, Hasegawa Y, Imagawa S, Mori N, Nagasawa T: Cytotoxic T-cell lymphoma arising in Behçet disease. Int J Hematol; 2003 Apr;77(3):282-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic T-cell lymphoma arising in Behçet disease.
  • The case of a 49-year-old man with peripheral T-cell lymphoma arising in Behcet disease (BD) is reported.
  • A diagnosis of incomplete BD was made, and the patient was treated with immunosuppressive agents for 9 months.
  • A left perirenal mass emerged, and a computed tomography-guided needle biopsy of the tumor revealed the infiltration of small- and medium-sized lymphoma cells.
  • A diagnosis of non-Hodgkin's lymphoma (diffuse medium, T-cell) was made.
  • Standard combination chemotherapy diminished the perirenal and orbital lesions.
  • Lymphoma cell infiltration in the esophagus was detected after chemotherapy, and the patient died of massive bleeding from the gastrointestinal tract.
  • Non-Hodgkin's lymphoma is rarely associated with BD, and only 7 cases have been reported in the literature.
  • We have summarized the published case reports of malignant lymphoma arising in BD.
  • To our knowledge, this case report is the first to describe cytotoxic T-cell lymphoma arising in Behçet disease.
  • [MeSH-major] Behcet Syndrome / complications. Lymphoma, T-Cell / etiology. T-Lymphocytes, Cytotoxic / pathology
  • [MeSH-minor] Antigens, CD / analysis. Clone Cells / immunology. Humans. Immunosuppressive Agents / therapeutic use. Kidney Neoplasms. Male. Middle Aged. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S46-55 [9894469.001]
  • [Cites] J Gastroenterol. 1997 Apr;32(2):241-5 [9085175.001]
  • [Cites] Ann Rheum Dis. 2001 Nov;60(11):996-1002 [11602462.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):317-26 [10830738.001]
  • [Cites] Arthritis Rheum. 1974 Jul-Aug;17(4):383-90 [4604718.001]
  • [Cites] No To Shinkei. 1992 Nov;44(11):1029-33 [1296716.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):296-301 [10680899.001]
  • [Cites] Int J Tissue React. 1988;10(2):59-65 [3053482.001]
  • [Cites] Ann Dermatol Venereol. 1990;117(11):885-7 [2099715.001]
  • [Cites] N Engl J Med. 1999 Oct 21;341(17):1284-91 [10528040.001]
  • [Cites] Ann Intern Med. 1976 Jan;84(1):68-76 [1106291.001]
  • [Cites] Intern Med. 1993 Aug;32(8):663-7 [8312668.001]
  • [Cites] Clin Rheumatol. 2001;20(4):239-44 [11529628.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):193-207 [10697278.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):313-23 [9578080.001]
  • [Cites] Rinsho Ketsueki. 1992 Feb;33(2):211-5 [1635171.001]
  • [Cites] Ann Rheum Dis. 1986 Sep;45(9):789 [3767471.001]
  • [Cites] Acta Pathol Jpn. 1974 Jan;24(1):141-50 [4406401.001]
  • [Cites] Arthritis Rheum. 1982 Nov;25(11):1343-51 [6215926.001]
  • [Cites] Arthritis Rheum. 1982 Sep;25(9):1130-3 [7126297.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1998 Oct;236(10):798-9 [9801898.001]
  • [Cites] Rinsho Ketsueki. 1997 Aug;38(8):657-62 [9311271.001]
  • [Cites] Nephron. 1999 Feb;81(2):239 [9933762.001]
  • [Cites] Cancer. 1995 Apr 1;75(7):1728-33 [8826934.001]
  • (PMID = 12731673.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Immunosuppressive Agents
  • [Number-of-references] 25
  •  go-up   go-down


15. Nizze H, Prall F, Wigger M, Eggers G, Knieling K, Parwaresch R: [Primary renal manifestation in malignant lymphomas and leukemia]. Pathologe; 2003 Oct;24(6):460-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary renal manifestation in malignant lymphomas and leukemia].
  • Primary manifestation of malignant lymphoma and/or leukaemia rarely occurs in the kidney.
  • It can be the cause of a hitherto unexplained acute renal failure or it is incidentally detected as shown in the three cases under report.1.A 68-year-old man was operated on because of a symptomatic tumour in his right kidney.
  • At nephrectomy, a conventional (clear cell) renal cell carcinoma was found simultaneously with an occult mantle cell lymphoma infiltrating the adjacent renal and extrarenal tissue.
  • Clinical follow-up uncovered nodal and bone marrow involvement, so that a primary renal manifestation of mantle cell lymphoma was apparent.2.A 69-year-old man with suspected vertebral metastasis underwent partial renal resection because of a mass in his left kidney.
  • Histologically and immunohistochemically, the renal infiltration was diagnosed as a precursor B-lymphoblastic lymphoma.
  • After chemotherapy and irradiation, leukaemic blood cell counts with 50% lymphoblasts proved a primary renal manifestation of precursor B-lymphoblastic leukaemia/lymphoma.3.A 13-year-old boy presented clinically with renal failure, enlarged kidneys, and normal urinalysis.
  • Renal biopsy showed a diffuse interstitial infiltration with atypical T-lymphoblasts compressing tubules and surrounding preserved glomeruli.
  • Subsequent clinical bone marrow smears presented 60% T-lymphoblasts, so that the final diagnosis of a primary renal manifestation of acute T-lymphoblastic leukaemia of mature thymic cortex type was made.
  • Immediate chemotherapy resulted in total recovery of renal function and bone marrow findings.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Kidney Neoplasms / pathology. Leukemia / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adolescent. Aged. Burkitt Lymphoma / pathology. Humans. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymphoma / pathology. Lymphoma / surgery. Lymphoma, B-Cell / pathology. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1991 Dec;96(6):738-45 [1746490.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):429-31 [12540447.001]
  • [Cites] Am J Surg Pathol. 1987 May;11(5):375-82 [3555131.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Urol. 1966 Apr;95(4):485-8 [5326510.001]
  • [Cites] Ann Pathol. 2002 Jun;22(3):222-5 [12410107.001]
  • [Cites] Cancer. 1987 Aug 1;60(3):386-91 [3594375.001]
  • [Cites] Gen Diagn Pathol. 1998 Apr;143(5-6):317-20 [9653914.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1986 Spring;8(1):8-12 [3487255.001]
  • [Cites] J Urol. 1983 Feb;129(2):364-7 [6572731.001]
  • [Cites] Pediatr Med Chir. 1982 Jan-Apr;4(1-2):107-13 [6955776.001]
  • [Cites] Arch Ital Urol Androl. 2002 Mar;74(1):44-7 [12053451.001]
  • (PMID = 14605852.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Manuelli M, De Luca L, Iaria G, Tatangelo P, Sforza D, Perrone L, Bellini MI, Angelico R, Anselmo A, Tisone G: Conversion to rapamycin immunosuppression for malignancy after kidney transplantation. Transplant Proc; 2010 May;42(4):1314-6
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conversion to rapamycin immunosuppression for malignancy after kidney transplantation.
  • INTRODUCTION: Malignancies are a well-known complication of immunosuppressive therapy among renal transplant recipients, representing an important cause of long-term morbidity and mortality.
  • Rapamycin has been shown to limit the proliferation of a number of malignant cell lines in vivo and in vitro.
  • METHODS: Fifteen patients developed the following malignancies at a mean of 90.3 months (range = 10-252) after kidney transplantation: metastatic gastric cancer (n = 1), metastatic colon cancer (n = 1), bilateral nephrourothelioma (n = 1), skin cancer (n = 2), Kaposi's sarcoma (n = 2), posttransplant lymphoproliferative disorder (PTLD; n = 4), renal cell carcinoma T1 (n = 1), MALT lymphoma (n = 1), intramucous colon carcinoma (n = 1), liposarcoma of the spermatic cord (n = 1).
  • After the diagnosis of malignancy, the patients were switched from calcineurin inhibitor-based immunosuppression to rapamycin (monotherapy, n = 3), or associated with steroids (n = 6) or with mycophenolate mofetil (n = 6).
  • RESULTS: Both patients with metastatic cancer underwent chemotherapy but succumbed after 6 and 13 months.
  • Two patients with PTLD who underwent chemotherapy died after 12 and 36 months.
  • Renal graft function remained stable in all other patients from diagnosis throughout follow-up.
  • Nevertheless, it is difficult to assess whether tumor regression was due to rapamycin treatment or to the reduced immunosuppression.
  • [MeSH-major] Kidney Transplantation / immunology. Neoplasms / immunology. Sirolimus / therapeutic use
  • [MeSH-minor] Cell Division / drug effects. Cell Line, Tumor. Colonic Neoplasms / immunology. Colonic Neoplasms / pathology. Genital Neoplasms, Male / immunology. Genital Neoplasms, Male / pathology. Humans. Immunosuppression / methods. Immunosuppressive Agents / therapeutic use. Liposarcoma / immunology. Liposarcoma / pathology. Male. Neoplasm Metastasis. Skin Neoplasms / immunology. Skin Neoplasms / pathology. Stomach Neoplasms / immunology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010. Published by Elsevier Inc.
  • (PMID = 20534289.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


17. Ulu EM, Tutar NU, Coskun M, Tore HG, Guvenc Z, Haberal M: Abdominal computed tomography findings of malignant tumors in patients with solid organ transplants. Transplant Proc; 2007 May;39(4):1066-70
MedlinePlus Health Information. consumer health - Organ Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal computed tomography findings of malignant tumors in patients with solid organ transplants.
  • The aim of this study was to characterize distribution and appearance of abdominal malignant tumors detected with spiral computed tomography (CT) examination in patients with solid organ transplantation.
  • All abdominal CT examinations were performed prior to immunomodulation or chemotherapy.
  • RESULTS: Eleven renal and one liver transplantation patient developed an abdominal malignancy.
  • In two patients the transplanted organ itself had malignant tumors: one patient had PTLD with Burkitt lymphoma in the transplanted liver and the other a renal cell carcinoma in the transplanted kidney.
  • CONCLUSIONS: The early diagnosis of abdominal malignancies after solid organ transplantation is crucial for the patient's prognosis, especially under immunosuppression.
  • [MeSH-minor] Abdomen. Adult. Female. Humans. Incidence. Kidney Transplantation / adverse effects. Male. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524893.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Buła G, Waler J, Niemiec A, Trompeta J, Steplewska K, Gawrychowski J: Unusual malignant thyroid tumours--a clinical study of 20 cases. Acta Chir Belg; 2008 Nov-Dec;108(6):702-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual malignant thyroid tumours--a clinical study of 20 cases.
  • The aim of this study is to assess late results of surgical treatment for primary non-Hodgkin lymphoma (PNHL), thyroid sarcomas (TS) and tumour metastases (TM) of the thyroid gland.
  • MATERIALS AND METHODS: Between January 1st, 1990 and December 31st, 2005, 12725 patients were surgically treated for various types of goitre.
  • Malignant tumour was diagnosed in 617 (4.9%) cases, consisting of 597 (96.8%) patients with thyroid carcinoma and 20 (3.2%) with other tumours, which included 9 (1.5%) cases of PNHL, 9 (1.5%) cases of TM and 2 (0.2%) patients who showed TS.
  • RESULTS: In the group of patients diagnosed with PNHL, variant B-cell lymphoma predominated (77.8%), and in cases of patients with TM renal cell carcinoma prevailed (77.8%).
  • All patients were surgically treated with possible complementary chemotherapy and/or radiotherapy.
  • Patients with primary thyroid lymphomas should be approached individually using all available methods of treatment, including surgery and radiotherapy and/or chemotherapy.
  • 2. Diagnosis of cold nodules in patients with oncological history should always arouse suspicion of metastases to the thyroid gland.
  • 3. Diagnosis of non-thyroid cancer prior to surgery is difficult to obtain.
  • [MeSH-major] Lymphoma, Non-Hodgkin / surgery. Sarcoma / surgery. Thyroid Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Female. Goiter / etiology. Humans. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Lymphoma, B-Cell / surgery. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241922.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


19. Rohr JC, Wagner HJ, Lauten M, Wacker HH, Jüttner E, Hanke C, Pohl M, Niemeyer CM: Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease. Pediatr Transplant; 2008 Jun;12(4):426-31
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease.
  • The development of lymphomas after SOT is a well-known complication of the immunosuppressive therapy necessary to prevent graft rejection.
  • Differentiating PTLD from malignant lymphomas, especially HL can be challenging.
  • We report on two patients, who developed EBV-associated lymphomas several years after SOT.
  • A histological examination of lymph nodes led to a diagnosis of HL in both patients, who were started on chemotherapy according to current treatment protocols.
  • In this patient, the EBV expression profile revealed a latency type III suggesting the diagnosis of Hodgkin-like PTLD.
  • The other patient required six courses of chemotherapy plus radiotherapy to reach a complete remission.
  • In his tumor cells, a restricted EBV-latency type II pattern was found, suggesting a diagnosis of classical HL.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / metabolism. Hodgkin Disease / etiology. Hodgkin Disease / virology. Kidney Transplantation / adverse effects. Liver Transplantation / adverse effects. Lymphoproliferative Disorders / etiology. Lymphoproliferative Disorders / virology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Cyclosporine / adverse effects. Diagnosis, Differential. Humans. Immunosuppressive Agents / adverse effects. Lymph Nodes / pathology. Male


20. Cairo MS, Coiffier B, Reiter A, Younes A, TLS Expert Panel: Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol; 2010 May;149(4):578-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.
  • With the increased availability of newer therapeutic targeted agents, such as rasburicase (recombinant urate oxidase), there are no published guidelines on the risk classification of TLS for individual patients at risk of developing this syndrome.
  • We convened an international TLS expert consensus panel to develop guidelines for a medical decision tree to assign low, intermediate and high risk to patients with cancer at risk for TLS.
  • Risk factors included biological evidence of laboratory TLS (LTLS), proliferation, bulk and stage of malignant tumour and renal impairment and/or involvement at the time of TLS diagnosis.
  • An international TLS consensus expert panel of paediatric and adult oncologists, experts in TLS pathophysiology and experts in TLS prophylaxis and management, developed a final model of low, intermediate and high risk TLS classification and associated TLS prophylaxis recommendations.
  • [MeSH-minor] Adult. Child. Decision Trees. Evidence-Based Medicine / methods. Humans. Kidney / physiopathology. Leukemia / drug therapy. Lymphoma / drug therapy. Multiple Myeloma / drug therapy. Neoplasms / drug therapy. Risk Assessment / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20331465.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 44
  • [Investigator] Cairo MS; Coiffier B; Reiter A; Younes A; Baruchel A; Bosly A; Goldman SC; Leverger G; Ohyashiki K; Panagiotidis P; Pession A; Pui CH; Ribera JM; Rosti G; Rule S; Tsukimoto I; Zinzani PL
  •  go-up   go-down


21. Moray G, Başaran O, Yağmurdur MC, Emiroğlu R, Bilgin N, Haberal M: Immunosuppressive therapy and Kaposi's sarcoma after kidney transplantation. Transplant Proc; 2004 Jan-Feb;36(1):168-70
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunosuppressive therapy and Kaposi's sarcoma after kidney transplantation.
  • Immunosuppressive therapy for organ transplant recipients is complicated by high rates of malignant diseases, one of which is Kaposi's sarcoma (KS).
  • At the time of KS diagnosis, 14 recipients were receiving cyclosporine, azathioprine, and prednisolone, and the other 2 azathioprine and prednisolone.
  • The mean time from transplantation to diagnosis was 24 +/- 15.2 months (range 8 to 74 months).
  • One recipient showed a lymphoma concomitant with KS.
  • After KS was confirmed, the first-line treatment was cyclosporine and azathioprine withdrawal with tapering of prednisolone.
  • The tumors were managed by appropriate surgical and/or medical therapy.
  • At the time of this presentation, 9 individuals are alive, 4 with normal renal function.
  • We found that the combination of immunosuppressive drug withdrawal and chemotherapy is effective in patients with limited disease, but the results are poor in cases of generalized disease.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Kidney Transplantation / immunology. Sarcoma, Kaposi / epidemiology
  • [MeSH-minor] Adult. Biopsy. Cadaver. Female. Humans. Immunosuppression / adverse effects. Immunosuppression / methods. Living Donors. Male. Retrospective Studies. Tissue Donors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15013336.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


22. Liu GH, Li HZ, Wang HJ, Mao QZ, Xia M, Xie Y, Xue C, Wang H, Ji ZG: [Occurrence, types, and therapies of malignant tumors in recipients of renal transplantation]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Jun;31(3):288-91
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Occurrence, types, and therapies of malignant tumors in recipients of renal transplantation].
  • OBJECTIVE: To investigate the types and therapies of malignancies in renal allograft recipients.
  • METHODS: We retrospectively analyzed the occurrence, types, and therapies of malignancies in 498 renal allograft recipients who had received operations in Peking Union Medical College Hospital from May 1986 to October 2008.
  • RESULTS: Among 498 renal allograft recipients, 18 patients (3.6% ) were diagnosed with malignancies, which included bladder cancer (n = 5), renal pyloric cancer or ureteric cancer (n = 4), leukemia or lymphoma (n = 3), hepatic cancer (n = 2), skin cancer, rectum carcinoma, pulmonary carcinoma and thymoma (n = 1 each).
  • One non-Hodgkin's lymphoma patient died 11 months after chemotherapy.
  • Five cases with advanced unresectable malignancies died 8 to 17 months after the diagnosis.
  • [MeSH-major] Kidney Transplantation. Neoplasms. Postoperative Complications

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621511.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Wu H, Wasik MA, Przybylski G, Finan J, Haynes B, Moore H, Leonard DG, Montone KT, Naji A, Nowell PC, Kamoun M, Tomaszewski JE, Salhany KE: Hepatosplenic gamma-delta T-cell lymphoma as a late-onset posttransplant lymphoproliferative disorder in renal transplant recipients. Am J Clin Pathol; 2000 Apr;113(4):487-96
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatosplenic gamma-delta T-cell lymphoma as a late-onset posttransplant lymphoproliferative disorder in renal transplant recipients.
  • We report 2 cases of renal transplant recipients in whom hepatosplenic gamma-delta T-cell lymphoma (gamma-delta HSTCL) developed 5 and 10 years after transplantation.
  • The malignant cells showed typical immunophenotype of gamma-delta T cells (CD2+, CD3+, CD4-, CD8-, CD7+, gamma-delta T-cell receptor-positive, and alpha-beta T-cell receptor-negative) with clonal T-cell receptor gene rearrangement and were of the V-delta-1 subset.
  • The malignant T cells in both cases were of host tissue origin.
  • Despite initial response to chemotherapy, both patients died within 6 months of diagnosis.
  • [MeSH-major] Kidney Transplantation / adverse effects. Liver Neoplasms / etiology. Lymphoma, T-Cell / etiology. Proteins. Receptors, Antigen, T-Cell, gamma-delta / immunology. Splenic Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10761449.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / Poly(A)-Binding Proteins; 0 / Proteins; 0 / RNA-Binding Proteins; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / Receptors, Interleukin-2; 0 / TIA1 protein, human
  •  go-up   go-down


24. Boratyńska M, Watorek E, Smolska D, Patrzałek D, Klinger M: Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc; 2007 Nov;39(9):2736-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The inhibition of mTOR is a target for anticancer drugs in posttransplant malignancies.
  • The influence of conversion to sirolimus after malignancy diagnosis was investigated on patient and renal allograft survivals.
  • The 20 renal allograft recipients (4 women, 16 men) of ages 26 to 73 years (mean, 59 years) developed malignancies within 6 to 172 months (mean, 53 months) after transplantation.
  • Three patients developed posttransplant lymphoproliferative disease (PTLD); four, Kaposi sarcoma, three, lung cancer; two, malignant melanoma; two, breast cancer; two, renal cell carcinoma; one, Merkel cell carcinoma; one, cutaneous T-cell lymphoma; one, larynx cancer; and one, gingival cancer.
  • After tumor diagnosis, calcineurin inhibitors, azathioprine, or mycophenolate mofetil (MMF) were discontinued abruptly and sirolimus introduced (2 mg/d; target trough level, 4.0 to 8.0 ng/mL).
  • The observation time of sirolimus therapy was 4 to 48 months (mean, 14 months).
  • Two patients with PTLD (large B-cell lymphoma) and four with Kaposi sarcoma had full regressions.
  • Eleven patients (larynx cancer, melanoma, breast cancer, T-cell lymphoma, renal cell carcinoma, Merkel cell carcinoma, and skin lymphoma) in addition to sirolimus therapy, underwent oncologic treatment, namely, surgery and/or chemotherapy.
  • One patient with T-cell lymphoma lost his graft; in the remaining patients, serum creatinine level was stable.
  • In conclusion, Conversion to sirolimus resulted in regression of large B-cell lymphoma and Kaposi sarcoma.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Kidney Transplantation / adverse effects. Lymphoma, B-Cell / drug therapy. Neoplasms / drug therapy. Neoplasms / epidemiology. Postoperative Complications / drug therapy. Sarcoma, Kaposi / drug therapy. Sirolimus / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunosuppressive Agents / therapeutic use. Lymphoproliferative Disorders / epidemiology. Male. Middle Aged. Retrospective Studies. Transplantation, Homologous


25. von Poblozki A, Dempke W, Schmoll HJ: [Carboxypeptidase-G2-rescue in a woman with methotrexate-induced renal failure]. Med Klin (Munich); 2000 Aug 15;95(8):457-60
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Carboxypeptidase-G2-Rescue bei einer Patientin mit Methotrexat-induziertem Nierenversagen.
  • BACKGROUND: Methotrexate (MTX) is a very effective chemotherapeutic drug, widely used in various malignant diseases for systemic therapy.
  • This results in a MTX-accumulation in the body tissue with subsequent massive toxic side effects.
  • CASE REPORT: We report on a 62-year-old woman with acute lymphoblastic leukemia (first diagnosis November 1997) receiving chemotherapy with 2,340 mg methotrexate over 24 hours.
  • [MeSH-major] Acute Kidney Injury / chemically induced. Acute Kidney Injury / drug therapy. Antimetabolites, Antineoplastic / adverse effects. Methotrexate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. gamma-Glutamyl Hydrolase / therapeutic use
  • [MeSH-minor] Creatinine / blood. Female. Humans. Infusions, Intravenous. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10985069.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; AYI8EX34EU / Creatinine; EC 3.4.19.9 / gamma-Glutamyl Hydrolase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


26. Kobayashi T, Muto S, Nemoto J, Miyata Y, Ishiharajima S, Hironaka M, Asano Y, Kusano E: Fanconi's syndrome and distal (type 1) renal tubular acidosis in a patient with primary Sjögren's syndrome with monoclonal gammopathy of undetermined significance. Clin Nephrol; 2006 Jun;65(6):427-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fanconi's syndrome and distal (type 1) renal tubular acidosis in a patient with primary Sjögren's syndrome with monoclonal gammopathy of undetermined significance.
  • Fanconi's syndrome is a far less frequent complication compared with distal tubular dysfunction.
  • At that time, biclonal spike on serum protein (IgG-kappa and IgA-kappa) and Bence-Jones protein in urine were found.
  • Thus, a diagnosis of monoclonal gammopathy of undetermined significance (MGUS) was made.
  • Laboratory evaluation showed inappropriate, alkaline urine in hyperchloremic metabolic acidosis and a positive urine anion gap, indicating the presence of distal (Type 1) renal tubular acidosis (RTA).
  • The kidney biopsy represented diffuse and severe tubulointerstitial nephritis with dense infiltrates of lymphocytes and IgA and K light chain-positive plasma cells.
  • No findings of multiple myeloma or malignant lymphoma were observed.
  • In conclusion, our patient had Sjögren's syndrome with MGUS and exhibited dysfunction of both proximal tubule (Fanconi's syndrome) and distal tubule, which may be attributed to diffuse tubulointerstitial nephritis.
  • [MeSH-major] Acidosis, Renal Tubular / complications. Fanconi Syndrome / diagnosis. Paraproteinemias / diagnosis. Sjogren's Syndrome / blood. Sjogren's Syndrome / complications
  • [MeSH-minor] Biopsy. Female. Humans. Kidney / pathology. Kidney / ultrastructure. Middle Aged


27. Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F, Montillo M, Nosari A, Morra E, Cooperative Study Group on PTLDs: Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica; 2002 Jan;87(1):67-77
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
  • BACKGROUND AND OBJECTIVES: Clinical and pathologic variability of post-transplant lymphoproliferative disorders (PTLDs), their aggressive behavior and the recognized therapy-related toxicity make management of patients with these disorders difficult.
  • Assessment of first-line treatment and identification of prognostic factors need to be better defined.
  • DESIGN AND METHODS: Data on 40 PTLDs which developed in adult solid organ recipients were analyzed in order to evaluate clinical and pathologic features, response to treatment and prognostic factors.
  • RESULTS: The median time from transplant to PTLD was 56 months.
  • Regarding histologic features, plasmacytic hyperplasia was diagnosed in 5 patients (12.5%), polymorphic lymphoproliferative disorders in 3 (7.5%), malignant lymphoma in 32 (80%).
  • The diagnosis was made at autopsy in eight patients (20%).
  • Twenty-nine patients completed their scheduled treatment and are evaluable for outcome.
  • The cumulative probability of survival at 1 year is 57% (CI 37.6-73.4) and the median survival time of the entire group has not been reached at 54 months.
  • Therapy tailored on histologic and clinical features of PTLD is feasible and is able to give long-lasting complete responses.
  • [MeSH-minor] Adult. Aged. Anti-Bacterial Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiviral Agents / therapeutic use. Female. Heart Transplantation / adverse effects. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter pylori / isolation & purification. Herpesvirus 4, Human / isolation & purification. Humans. Immunocompromised Host. Interleukin-10 / blood. Kidney Transplantation / adverse effects. Life Tables. Liver Transplantation / adverse effects. Lung Transplantation / adverse effects. Male. Middle Aged. Prognosis. Proportional Hazards Models. Remission Induction. Retrospective Studies. Risk Factors. Rituximab. Survival Analysis. Survival Rate. Time Factors. Treatment Outcome. Viral Load

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11801467.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antiviral Agents; 130068-27-8 / Interleukin-10; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


28. Ivry S, Shteinmintz D, Tabenkin H: [Carbamazepine hypersensitivity symptoms]. Harefuah; 2000 Apr 2;138(7):545-7, 614
Hazardous Substances Data Bank. CARBAMAZEPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The syndrome usually develops between 1 week and 3 months after starting therapy, with involvement of the liver, lung, kidney and inappropriate secretion of ADH.
  • With onset of CHS, the drug must be stopped and if there is no improvement, cortico-steroids should be started.
  • When the diagnosis is in doubt, the patch test, lymphocyte transformation test, macrophage migration inhibitor factor, and other tests can be helpful.
  • It is not known whether the CHS syndrome should be considered a premalignant state, with increased risk for the development of malignant lymphoma.
  • [MeSH-major] Analgesics, Non-Narcotic / adverse effects. Carbamazepine / adverse effects. Drug Hypersensitivity. Trigeminal Neuralgia / drug therapy

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • MedlinePlus Health Information. consumer health - Trigeminal Neuralgia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10883181.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] ISRAEL
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 33CM23913M / Carbamazepine
  •  go-up   go-down


29. Siemens HJ, Gerke P, Steinhoff J, Roth-Isigkeit A, Wagner K, Brückner S: A prolonged APTT in a patient with a low grade malignant NHL - a case report. Haematologica; 2002 Feb;87(2):ELT08
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prolonged APTT in a patient with a low grade malignant NHL - a case report.
  • [MeSH-major] Autoantibodies / immunology. Factor IX / immunology. Lymphoma, B-Cell / blood. Lymphoma, Non-Hodgkin / blood. Partial Thromboplastin Time
  • [MeSH-minor] Anemia / etiology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Coagulation Factors / analysis. Blood Coagulation Factors / therapeutic use. Chlorambucil / administration & dosage. Diagnosis, Differential. Female. Humans. Immunocompromised Host. Kidney Transplantation. Liver / ultrasonography. Middle Aged. Mitoxantrone / administration & dosage. Palliative Care. Postoperative Complications. Prednisolone / administration & dosage. Prothrombin Time. Splenomegaly / drug therapy. Splenomegaly / etiology. Thrombocytopenia / etiology

  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11836185.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Blood Coagulation Factors; 18D0SL7309 / Chlorambucil; 37224-63-8 / prothrombin complex concentrates; 9001-28-9 / Factor IX; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down






Advertisement